REDWOOD CITY, Calif., Nov. 5, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today ...

REDWOOD CITY, Calif., May 14, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, ...

Nevro1™ Proven to Immediately Transfix Sacroiliac (SI) Joint to Allow for Long-term SI Joint Fusion REDWOOD CITY, Calif., Feb. 28, 2024 /PRNewswire/ -- Nevro Corp. (NVRO), a global medical device ...

Shares of Nevro Corp. NVRO gained 5% on Oct 13, following the announcement of the FDA approval for its spinal cord stimulation (SCS) system — Senza HFX iQ — for the treatment of chronic pain. The new ...

Senza® HFX iQ™ is the First and Only SCS System that Uses Artificial Intelligence to Optimize and Maintain Pain Relief Using Each Patient's Response REDWOOD CITY, Calif., March 7, 2023 /PRNewswire/ -- ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Nevro Corporation has announced the appointment of Michael DeMane as President and Chief Executive Officer effective immediately. He will also join the company's ...

Nevro Corp. NVRO recently announced the receipt of the FDA’s approval for its Senza System for the treatment of chronic pain associated with Painful Diabetic Neuropathy (“PDN”). The approval is, ...

REDWOOD CITY, Calif., May 14, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, ...